With the global pandemic and the continuous mutations of severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), the need for effective and broadly neutralizing …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

Coronaviruses have been the causative agent of three epidemics and pandemics in the past
two decades, including the ongoing COVID-19 pandemic. A broadly-neutralizing …

The emerging coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2), is the causative agent of coronavirus disease 2019 (COVID‐19), which has become a …

The rapid adaptation of SARS‐CoV‐2 within the host species and the increased viral
transmission triggered the evolution of different SARS‐CoV‐2 variants. Though numerous …

Currently circulating SARS-CoV-2 variants have gained complete or significant resistance to
all SARS-CoV-2-neutralizing antibodies that have been used in the clinic. Such antibodies …

The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Broadly neutralizing antibodies against severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) variants are sought to curb coronavirus disease 2019 (COVID‐19) …

The continuous emergence of novel severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants poses new challenges in the fight against the coronavirus disease …